ORKA's Quality Score rose 4 points on Fri, Nov 6, to 7. Buying reached its highest in 20 days (4 chart checks started).
Follow ORKA's trial news. Pro members can get an alert when Oruka Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Up 28% from Oct 23 to Nov 6 while the S&P 500 fell 3%.
| Outperforming | Up 277% in a year vs the S&P's +9% |
| Latest filing | S-3, Aug 21 |
ReportExpected to report Wednesday, before the open. Every 3 months, a company tells everyone how much it sold and earned. It rose after 2 and fell after 2 of its last 4 reports, +4.0% on average. Past reports ›
Oruka reports positive phase 2b psoriasis trial results By Investing.com
ORKA closed +12.7% that day on 2.1x normal volume.
Tue Nov 10: Guggenheim 3rd Annual Global…Investor conference · date confirmed.
3 more dates ahead: conferences, for Pro members.
After its last 4 reports it closed +4.0% on average, higher 2 of 4 times.
Over 5 years
No shelf registration or at-the-market program on file in the last three years.
CEO Lawrence Otto Klein sold 25,000 shares on Nov 2, under a planned sale. 41 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
Averagefor quality, not price, 8 of 14 chart checks firingWhat the Quality Score means
Well above its recent run. ORKA scores 7 today, against a median of 2.5 over its last 20 recorded sessions.
ORKA is #59 of 281 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 59 |
Cash and short-term investments: ORKA $874M, VRDN $982M, IRON $718M, EWTX $72.3M.
Expected to report Wed Nov 11, before the open (in 2 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“Other income, net was $8.9 million for the second quarter of 2026, compared to $3.9 million for the second quarter of 2025, driven primarily by interest earned on higher cash and marketable securities.”
ORKA's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“The Company expects that its cash, cash equivalents, and marketable securities will be sufficient to fund operations through an anticipated BLA filing for ORKA-001 and continued development of ORKA-002.”
From its results filing (SEC filing · Aug 10)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Aug 10, 2026 | -2.3% | +6.4% | +12.4% |
| Apr 30, 2026 | +0.5% | -8.5% | -6.3% |
| Mar 12, 2026 | +2.7% | +25.0% | +21.4% |
RSI 66.6, MACD above signal, above both averages. Not scored.
4 insiders sold $301M across 7 filings in the last 6 months. No open-market buys on record. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: ORKA is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and other conditions.
ORKA scores 7 today, which Breakaway calls Average. It is #59 of 281 in Biotech by Quality Score, with 8 of 14 chart checks firing. Up 28% from Oct 23 to Nov 6 while the S&P 500 fell 3%. Cash lasts over 5 years at its spending (to Jun 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
ORKA scores 7 today, which Breakaway calls Average (6 to 10). That is #59 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind ORKA's 7.
4 insiders sold $301M across 7 filings in the last 6 months. No open-market buys on record. The newest is Lawrence Otto Klein, Chief Executive Officer, who sold $235K on Sep 15. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until tomorrow morning. No account. No card. Then keep going with a free account.